ArticleEuropean radiology2025
MRI-based scoring systems for selective lateral lymph node dissection in locally advanced low rectal cancer after neoadjuvant chemoradiotherapy.
Article in European radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo develop scoring systems to predict the need for selective lateral lymph node dissection (LLND) alongside total mesorectal excision (TME) in patients with locally advanced low rectal cancer after neoadjuvant chemoradiotherapy (nCRT), focusing on lateral local recurrence (LLR) and lateral lymph node (LLN) metastasis. MATERIALS AND
methodsThis retrospective study included 607 patients with mrT3/T4 rectal cancer located within 8 cm of the anal verge who underwent nCRT and TME. A development group was used to develop a scoring system predicting the necessity of LLND using logistic regression analysis, incorporating primary tumor and LLN features observed on rectal MRI. External validation was performed in an independent group of 144 patients. We also analyzed risk factors for recurrence and residual LLNs after LLND.
resultsModel 1 included pretreatment LLN size and extramural venous invasion (EMVI). Model 2 incorporated pretreatment internal iliac and obturator lymph node sizes, EMVI, and nonresponsive LLN on restaging MRI. Model 3 focused solely on nonresponsive LLN on restaging MRI. In the development group, Models 1 and 2 exhibited better performance (area under the curve (AUC) = 0.92 and 0.90, respectively) than Model 3 (AUC = 0.79), consistent with the validation group. Among patients who underwent LLND, the distal internal iliac compartment had more residual lymph nodes than other compartments (p = 0.02).
conclusionScoring systems utilizing LLN features and EMVI on MRI might aid in decision-making for selective LLND following nCRT in locally advanced low rectal cancer. KEY POINTS: Question The criteria for when additional lateral lymph node dissection (LLND) may benefit in locally advanced low rectal cancer have not yet been definitively established. Findings Scoring systems (Model 1, 2) based on preoperative MRI utilize lateral lymph node (LLN) size and extramural venous invasion to predict the necessity of LLND. Clinical relevance The selective LLND along with total mesorectal excision aids in managing LLN metastasis and lateral local recurrence in locally advanced low rectal cancer after neoadjuvant chemoradiotherapy. The imaging-based scoring systems may guide clinical decision-making for selective LLND.
Indexed as
Identifiers
39939420What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.